Global Respiratory Virus Vaccines Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Respiratory Virus Vaccines Market is presumed to reach the market size of nearly USD 22.92 Billion by 2032 from USD 10.95 Billion in 2023 with a CAGR of 8.55% under the study period 2024-2032.

A vaccine is a biological preparation that is used to provide acquired immunity against numerous harmful pathogens. It is administered to prevent the vulnerable population from a specific disease. It contains an agent, i.e., bacteria or virus strain, which causes a particular disease in a weakened or killed form. Respiratory disease is a disease that impacts the lungs and other parts of the body's respiratory system. It can be caused due to smoking, passive smoking, infection, asbestos, and another type of air pollution. Respiratory diseases consist of asthma, pulmonary fibrosis, pneumonia, COPD, and lung cancer COPD and asthma cause breathing difficulty due to swelling of the air passage and blockage due to mucus. Specific vaccine-preventable diseases can cause swelling of air passage and lungs. The mixing of the two can prompt pneumonia and various genuine respiratory diseases. Immunization is considered the most secure way to ensure a person's wellbeing, regardless of whether the sufferer is taking prescribed medications. Vaccine reactions are generally mild and fade away on their own. Serious side effects are exceptionally uncommon.

MARKET DYNAMICS

The market is driven by factors such as the increasing prevalence of respiratory diseases and the increasing number of under-trial vaccines, whereas lack of inadequate delivery infrastructure and limited consumer awareness are restraining factors. Increasing expenditure on Research & Development and the growing availability of vaccines through various market collaborations create opportunities for market growth. In addition, R&D on respiratory vaccines is focused on COVID-19 at the moment; however, the long-term outlook remains positive. Learning from the impact of COVID-19, governments across the globe focus on developing adequate treatment options for respiratory vaccines.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Respiratory Virus Vaccines. The growth and trends of Respiratory Virus Vaccines industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Respiratory Virus Vaccines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Inactivated/Killed
Vaccines
Live-attenuated Vaccines
Recombinant Vaccines

By Route of Administration

Intramuscular
Intranasal
Subcutaneous

By Indication

Influenza
Measles, Mumps & Rubella
Coronavirus Disease (COVID-19)
Others

By Age Group

Pediatric
Adults

By End User

Physician's Office
Hospitals
Clinics
Pharmacies/Stores

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Respiratory Virus Vaccines market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Respiratory Virus Vaccines market include CSL Limited, Sanofi, AstraZeneca, Merck & Co. Inc., GlaxoSmithKline Plc, Serum Institute Of India Pvt. Ltd., Bharat Biotech, Sinovac Biotech Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11215029

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. RESPIRATORY VIRUS VACCINES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Indication
- 3.7.4 Market Attractiveness Analysis By Age Group
- 3.7.5 Market Attractiveness Analysis By End User
- 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Inactivated/Killed Historic and Forecast Sales By Regions
5.4. Vaccines Historic and Forecast Sales By Regions
5.5. Live-attenuated Vaccines Historic and Forecast Sales By Regions
5.6. Recombinant Vaccines Historic and Forecast Sales By Regions

6. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Intramuscular Historic and Forecast Sales By Regions
6.4. Intranasal Historic and Forecast Sales By Regions
6.5. Subcutaneous Historic and Forecast Sales By Regions

7. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY INDICATION

7.1. Overview By Indication
7.2. Historical and Forecast Data Analysis By Indication
7.3. Influenza Historic and Forecast Sales By Regions
7.4. Measles, Mumps & Rubella Historic and Forecast Sales By Regions
7.5. Coronavirus Disease (COVID-19) Historic and Forecast Sales By Regions
7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY AGE GROUP

8.1. Overview By Age Group
8.2. Historical and Forecast Data Analysis By Age Group
8.3. Pediatric Historic and Forecast Sales By Regions
8.4. Adults Historic and Forecast Sales By Regions

9. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY END USER

9.1. Overview By End User
9.2. Historical and Forecast Data Analysis By End User
9.3. Physician's Office Historic and Forecast Sales By Regions
9.4. Hospitals Historic and Forecast Sales By Regions
9.5. Clinics Historic and Forecast Sales By Regions
9.6. Pharmacies/Stores Historic and Forecast Sales By Regions

10. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE RESPIRATORY VIRUS VACCINES COMPANIES

11.1. Respiratory Virus Vaccines Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12. COMPANY PROFILES OF RESPIRATORY VIRUS VACCINES INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. CSL Limited
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
12.4. Sanofi
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
12.5. AstraZeneca
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
12.6. Merck & Co. Inc.
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
12.7. GlaxoSmithKline Plc
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
12.8. Serum Institute Of India Pvt. Ltd.
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
12.9. Bharat Biotech
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
12.10. Sinovac Biotech Ltd
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies